(Q43684895)

25 November 2017

Antibody-dependent enhancement of human immunodeficiency virus type 1 infection (English)

1 reference

25 November 2017

1 reference

W E Robinson

1

1 reference

25 November 2017

D C Montefiori

series ordinal

2

1 reference

25 November 2017

W M Mitchell

series ordinal

3

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 April 1988

1 reference

25 November 2017

1 reference

25 November 2017

1

1 reference

25 November 2017

790-794

1 reference

25 November 2017

8589

1 reference

Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991657-1

7 January 2021

AIDS vaccine trial OKed

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991657-1

7 January 2021

Immunization against AIDS in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991657-1

7 January 2021

Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991657-1

7 January 2021

Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991657-1

7 January 2021

Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991657-1

7 January 2021

Variable and conserved neutralization antigens of human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991657-1

7 January 2021

Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991657-1

7 January 2021

Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991657-1

7 January 2021

Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991657-1

7 January 2021

Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991657-1

7 January 2021

A human immunodeficiency virus type 1 (HIV-1) infection-enhancing factor in seropositive sera

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991657-1

7 January 2021

Increase of retroviral infection in vitro by the binding of antiretroviral antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991657-1

7 January 2021

Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991657-1

7 January 2021

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991657-1

7 January 2021

AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991657-1

7 January 2021

10.1016/S0140-6736(88)91657-1

Identifiers

DOI

1 reference

25 November 2017

1 reference